% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Wiels:277426,
      author       = {Wiels, Wietse A and Oomens, Julie E and Engelborghs,
                      Sebastiaan and Baeken, Chris and von Arnim, Christine A F
                      and Boada, Mercè and Didic, Mira and Dubois, Bruno and
                      Fladby, Tormod and van der Flier, Wiesje M and Frisoni,
                      Giovanni B and Fröhlich, Lutz and Gill, Kiran Dip and
                      Grimmer, Timo and Hildebrandt, Helmut and Hort, Jakub and
                      Itoh, Yoshiaki and Iwatsubo, Takeshi and Klimkowicz-Mrowiec,
                      Aleksandra and Lee, Dong Young and Lleó, Alberto and
                      Martinez-Lage, Pablo and de Mendonça, Alexandre and Meyer,
                      Philipp T and Kapaki, Elisabeth N and Parchi, Piero and
                      Pardini, Matteo and Parnetti, Lucilla and Popp, Julius and
                      Rami, Lorena and Reiman, Eric M and Rinne, Juha O and
                      Rodrigue, Karen M and Sánchez-Juan, Pascual and Santana,
                      Isabel and Sarazin, Marie and Scarmeas, Nikolaos and Skoog,
                      Ingmar and Snyder, Peter J and Sperling, Reisa A and
                      Villeneuve, Sylvia and Wallin, Anders and Wiltfang, Jens and
                      Zetterberg, Henrik and Ossenkoppele, Rik and Verhey, Frans R
                      J and Vos, Stephanie J B and Visser, Pieter Jelle and
                      Jansen, Willemijn J and Alcolea, Daniel and Altomare,
                      Daniele and Baiardi, Simone and Baldeiras, Ines and Bateman,
                      Randall J and Blennow, Kaj and Bottlaender, Michel and den
                      Braber, Anouk and van Buchem, Mark A and Byun, Min Soo and
                      Cerman, Jirí and Chen, Kewei and Chipi, Elena and Day,
                      Gregory S and Drzezga, Alexander and Eckerström, Marie and
                      Ekblad, Laura L and Epelbaum, Stéphane and Förster, Stefan
                      and Fortea, Juan and Freund-Levi, Yvonne and Frings, Lars
                      and Guedj, Eric and Hausner, Lucrezia and Hellwig, Sabine
                      and Huey, Edward D and Jiménez-Bonilla, Julio F and
                      Johnson, Keith A and Juaristi, Ane Iriondo and Kandimalla,
                      Ramesh and Paraskevas, George and Kern, Silke and Kirsebom,
                      Bjørn-Eivind S and Kornhuber, Johannes and Lagarde, Julien
                      and Landau, Susan M and Legdeur, Nienke and Llibre Guerra,
                      Jorge J and Maserejian, Nancy N and Marquié, Marta and
                      Minatani, Shinobu and Morbelli, Silvia Daniela and Mroczko,
                      Barbara and Ntanasi, Eva and de Oliveira, Catarina Resende
                      and Olivieri, Pauline and Orellana, Adelina and Perrin,
                      Richard J and Peters, Oliver and Prabhakar, Sudesh and
                      Ramakers, Inez H and Rodríguez-Rodriguez, Eloy and Ruiz,
                      Agustín and Rüther, Eckart and Selnes, Per and Silva, Dina
                      and Soininen, Hilkka and Spiru, Luiza and Takeda, Akitoshi
                      and Teichmann, Marc and Tijms, Betty M and Teunissen,
                      Charlotte E and Thompson, Loisa I and Vogelgsangs, Jonathan
                      and Vöglein, Jonathan and Waldemar, Gunhild and Wallin,
                      Åsa K and Yannakoulia, Mary and Yi, Dahyun and Zettergren,
                      Anna},
      collaboration = {group, Amyloid Biomarker Study and Initiative,
                      Alzheimer’s Disease Neuroimaging},
      title        = {{D}epressive {S}ymptoms and {A}myloid {P}athology.},
      journal      = {JAMA psychiatry},
      volume       = {82},
      number       = {3},
      issn         = {2168-622X},
      address      = {Chicago, Ill.},
      publisher    = {AMA},
      reportid     = {DZNE-2025-00409},
      pages        = {296 - 310},
      year         = {2025},
      abstract     = {Depressive symptoms are associated with cognitive decline
                      in older individuals. Uncertainty about underlying
                      mechanisms hampers diagnostic and therapeutic efforts. This
                      large-scale study aimed to elucidate the association between
                      depressive symptoms and amyloid pathology.To examine the
                      association between depressive symptoms and amyloid
                      pathology and its dependency on age, sex, education, and
                      APOE genotype in older individuals without
                      dementia.Cross-sectional analyses were performed using data
                      from the Amyloid Biomarker Study data pooling initiative.
                      Data from 49 research, population-based, and memory clinic
                      studies were pooled and harmonized. The Amyloid Biomarker
                      Study has been collecting data since 2012 and data
                      collection is ongoing. At the time of analysis, 95 centers
                      were included in the Amyloid Biomarker Study. The study
                      included 9746 individuals with normal cognition (NC) and
                      3023 participants with mild cognitive impairment (MCI) aged
                      between 34 and 100 years for whom data on amyloid
                      biomarkers, presence of depressive symptoms, and age were
                      available. Data were analyzed from December 2022 to February
                      2024.Amyloid-β1-42 levels in cerebrospinal fluid or amyloid
                      positron emission tomography scans were used to determine
                      presence or absence of amyloid pathology. Presence of
                      depressive symptoms was determined on the basis of validated
                      depression rating scale scores, evidence of a current
                      clinical diagnosis of depression, or self-reported
                      depressive symptoms.In individuals with NC (mean [SD] age,
                      68.6 [8.9] years; 5664 $[58.2\%]$ female; 3002 $[34.0\%]$
                      APOE ε4 carriers; 937 $[9.6\%]$ had depressive symptoms;
                      2648 $[27.2\%]$ had amyloid pathology), the presence of
                      depressive symptoms was not associated with amyloid
                      pathology (odds ratio [OR], 1.13; $95\%$ CI, 0.90-1.40; P =
                      .29). In individuals with MCI (mean [SD] age, 70.2 [8.7]
                      years; 1481 $[49.0\%]$ female; 1046 $[44.8\%]$ APOE ε4
                      carriers; 824 $[27.3\%]$ had depressive symptoms; 1668
                      $[55.8\%]$ had amyloid pathology), the presence of
                      depressive symptoms was associated with a lower likelihood
                      of amyloid pathology (OR, 0.73; $95\%$ CI 0.61-0.89; P =
                      .001). When considering subgroup effects, in individuals
                      with NC, the presence of depressive symptoms was associated
                      with a higher frequency of amyloid pathology in APOE ε4
                      noncarriers (mean difference, $5.0\%;$ $95\%$ CI 1.0-9.0; P
                      = .02) but not in APOE ε4 carriers. This was not the case
                      in individuals with MCI.Depressive symptoms were not
                      consistently associated with a higher frequency of amyloid
                      pathology in participants with NC and were associated with a
                      lower likelihood of amyloid pathology in participants with
                      MCI. These findings were not influenced by age, sex, or
                      education level. Mechanisms other than amyloid accumulation
                      may commonly underlie depressive symptoms in late life.},
      keywords     = {Humans / Female / Male / Aged / Depression / Middle Aged /
                      Cross-Sectional Studies / Cognitive Dysfunction / Amyloid
                      beta-Peptides: cerebrospinal fluid / Amyloid beta-Peptides:
                      metabolism / Positron-Emission Tomography / Aged, 80 and
                      over / Adult / Biomarkers: cerebrospinal fluid / Peptide
                      Fragments: cerebrospinal fluid / Apolipoprotein E4: genetics
                      / Age Factors / Amyloid beta-Peptides (NLM Chemicals) /
                      Biomarkers (NLM Chemicals) / Peptide Fragments (NLM
                      Chemicals) / amyloid beta-protein (1-42) (NLM Chemicals) /
                      Apolipoprotein E4 (NLM Chemicals)},
      cin          = {AG Boecker / Clinical Research (Munich)},
      ddc          = {610},
      cid          = {I:(DE-2719)1011202 / I:(DE-2719)1111015},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      experiment   = {EXP:(DE-2719)DIAN-20090101},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39841452},
      pmc          = {pmc:PMC11883504},
      doi          = {10.1001/jamapsychiatry.2024.4305},
      url          = {https://pub.dzne.de/record/277426},
}